Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

Hodgkin Lymphoma ◽

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Phase 2 Trial ◽

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

British Journal of Haematology ◽

10.1111/bjh.15552 ◽

2018 ◽

Vol 184 (2) ◽

pp. 215-222 ◽

Cited By ~ 15

Author(s):

David J. Andorsky ◽

Kathryn S. Kolibaba ◽

Sarit Assouline ◽

Andres Forero‐Torres ◽

Vicky Jones ◽

...

Keyword(s):

Mantle Cell Lymphoma ◽

Hodgkin Lymphoma ◽

Cell Lymphoma ◽

Phase 2 ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Phase 2 Trial ◽

Mantle Cell ◽

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30909-9 ◽

2018 ◽

Vol 19 (1) ◽

pp. 65-75 ◽

Cited By ~ 144

Author(s):

Jeffrey A Jones ◽

Anthony R Mato ◽

William G Wierda ◽

Matthew S Davids ◽

Michael Choi ◽

...

Keyword(s):

Interim Analysis ◽

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30414-5 ◽

2018 ◽

Vol 19 (9) ◽

pp. 1215-1228 ◽

Cited By ~ 46

Author(s):

Paula Cramer ◽

Julia von Tresckow ◽

Jasmin Bahlo ◽

Sandra Robrecht ◽

Petra Langerbeins ◽

...

Keyword(s):

Primary Endpoint ◽

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356653.793538193 ◽

2017 ◽

Author(s):

Varsha Gandhi ◽

Prithviraj Bose

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1759055 ◽

2020 ◽

Vol 61 (9) ◽

pp. 2103-2112 ◽

Cited By ~ 5

Author(s):

Luke Coyle ◽

Nicholas J. Morley ◽

Alessandro Rambaldi ◽

Kylie D. Mason ◽

Gregor Verhoef ◽

...

Keyword(s):

B Cell ◽

Hodgkin Lymphoma ◽

Salvage Therapy ◽

Phase 2 ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Phase 2 Study ◽

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(16)30019-5 ◽

2016 ◽

Vol 17 (6) ◽

pp. 768-778 ◽

Cited By ~ 418

Author(s):

Stephan Stilgenbauer ◽

Barbara Eichhorst ◽

Johannes Schetelig ◽

Steven Coutre ◽

John F Seymour ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00455-1 ◽

2021 ◽

Author(s):

Matthew S Davids ◽

Benjamin L Lampson ◽

Svitlana Tyekucheva ◽

Zixu Wang ◽

Jessica C Lowney ◽

...

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Frontline Treatment ◽

Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70161-5 ◽

2014 ◽

Vol 15 (7) ◽

pp. 757-766 ◽

Cited By ~ 62

Author(s):

Bertram Glass ◽

Justin Hasenkamp ◽

Gerald Wulf ◽

Peter Dreger ◽

Michael Pfreundschuh ◽

...

Keyword(s):

Stem Cell ◽

Stem Cell Transplantation ◽

Hodgkin Lymphoma ◽

Cell Transplantation ◽

Allogeneic Stem Cell Transplantation ◽

Phase 2 ◽

Open Label ◽

Non Hodgkin Lymphoma ◽

Phase 2 Trial

Faculty Opinions recommendation of Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726356653.793525469 ◽

2016 ◽

Author(s):

Scott Kaufmann ◽

Wei Meng

Keyword(s):

Lymphocytic Leukaemia ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Dose-Adjusted EPOCH Regimen as First-Line Treatment for Non-Hodgkin's Lymphoma with Hemophagocytic Lymphohistiocytosis: A Single-Arm, Open-Label, Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3304299 ◽

2018 ◽

Author(s):

Jin-Hua Liang ◽

Li Wang ◽

Hua-Yuan Zhu ◽

Jun Qian ◽

Hui Liao ◽

...

Keyword(s):

Hemophagocytic Lymphohistiocytosis ◽

Hodgkin's Lymphoma ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Non Hodgkin's Lymphoma ◽

Open Label Phase ◽

First Line Treatment